Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services
China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...
Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...
MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...
Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...
Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027
China’s State Council has released the “Opinions on Fully Deepening the Reform of Drug and...
Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...
AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...
Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...
WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval
China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...
Shanghai Enacts New Regulations for Drug and Medical Device Administration
The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...
Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials
Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...
Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...
Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...
MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...